RESULTS -Baseline characteristics are given in Table 1 . The placebo group accounted for almost one-half of the patient withdrawals, primarily due to ineffective therapy. Withdrawals due to adverse events were infrequent and occurred at a comparable level in all groups ( • 
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Body weight decreased in all treatment groups, with a maximum estimated loss of 2.99 kg in the 1.90 mg liraglutide group. The difference compared with placebo was significant for the 1 The overall fractions of patients with adverse events were comparable across the four groups, ranging from 43 to 51% of patients. The fractions of patients reporting a gastrointestinal adverse event were 37, 29, 38, and 23% of patients for 1.90 mg, 1.25 mg, 0.65 mg, and placebo, respectively (NS), with a higher event rate reported at the highest dose group in comparison with placebo (P Ͻ 0.05). The individual gastrointestinal adverse events were reported at similar frequencies across the liraglutide treatment groups, although nausea seemed somewhat higher in the 1.90 and 0.65 mg groups (10% of subjects vs. 2-3% in the 1.25 mg and placebo groups, respectively). Diarrhea was reported by 26 of 123 and 5 of 40, nausea by 9 of 123 and 1 of 40, and vomiting by 4 of 123 and 0 of 40 subjects treated with liraglutide and placebo, respectively. Only 4 of 123 liraglutidetreated patients withdrew from the study because of gastrointestinal adverse events. The incidence of gastrointestinal adverse events decreased over time. The effect on body weight did not change when excluding patients with duration of gastrointestinal events Ͼ7 days. Three serious adverse events were reported by two patients (one in the placebo group and one in the 1.90 mg group [influenza]). No major or minor hypoglycemic episodes were reported. There was no treatment- Data are means Ϯ SD or median (range) unless otherwise indicated. Data for age, sex, duration of diabetes, and previous treatment were recorded at screening and diabetes characteristics at baseline. Two patients withdrew from the study before receiving study medication; one because of withdrawal of consent and one because of noncompliance. The adverse event withdrawals were as follows: placebo: blood glucose increased (2 patients), hyperglycemia/nausea; 0.65 mg: diarrhea; 1.25 mg: injection site rash; and 1.90 mg: tachypnoea/gastrooesophageal reflux disease, constipation. ITT, intent to treat.
related effect on induction of antibodies and no clinically relevant changes in safety laboratory parameters, including thyroid ultrasonography, were observed after treatment with liraglutide.
CONCLUSIONS -T h e p r e s e n t study demonstrated sustained effect of the long-acting GLP-1 analog liraglutide on glycemic control in patients with type 2 diabetes without any major or minor hypoglycemic episodes. At the highest dose, liraglutide monotherapy reduced the estimated average A1C levels by 1.74% from an average A1C of 8.5%, when compared with placebo. When given one of the two highest doses of liraglutide, almost one-half of the patients managed to reach the American Diabetes Association target for postprandial control (7), confirming a full 24-h coverage of liraglutide on glycemic control (2). Furthermore, in spite of improved glycemic control, which is often associated with an increase in body weight (8), a dosedependent decrease in body weight was seen. Adverse events related to the gastrointestinal system and headaches were the most frequently reported adverse events. In addition to a beneficial effect of liraglutide on ␤-cell function, in current and in previous studies (9 -11), a potential effect on lowering of blood pressure was observed in the current study. The mechanism behind the effect on blood pressure remains unknown. However, since the effect on blood pressure occurred earlier than the effect on body weight, it suggests that the effect cannot only be ascribed to the lowering in body weight. In conclusion, the long-acting, once-daily GLP-1 analog, liraglutide, targets well-described abnormalities in the type 2 diabetes phenotype.
